Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.54M | 5.18M | 19.22M | 14.75M | 4.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.54M | 5.18M | 19.22M | 14.75M | 4.55M |
| Cost of Revenue | 110.22M | 135.75M | 148.80M | 151.46M | 111.13M |
| Gross Profit | -74.68M | -130.57M | -129.57M | -136.72M | -106.58M |
| SG&A Expenses | 42.17M | 41.63M | 46.65M | 54.65M | 77.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.39M | 177.38M | 195.45M | 206.11M | 188.31M |
| Operating Income | -116.85M | -172.20M | -176.23M | -191.37M | -183.77M |
| Income Before Tax | -108.10M | -162.25M | -171.90M | -202.65M | -178.90M |
| Income Tax Expenses | 20.00K | 3.00K | -- | -158.00K | 7.00K |
| Earnings from Continuing Operations | -108.12M | -162.25M | -171.90M | -202.49M | -178.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.12M | -162.25M | -171.90M | -202.49M | -178.91M |
| EBIT | -116.85M | -172.20M | -176.23M | -191.37M | -183.77M |
| EBITDA | -97.37M | -151.16M | -152.38M | -172.04M | -170.82M |
| EPS Basic | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 |
| Normalized Basic EPS | -0.14 | -0.23 | -0.26 | -0.31 | -0.33 |
| EPS Diluted | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 |
| Normalized Diluted EPS | -0.14 | -0.23 | -0.26 | -0.31 | -0.33 |
| Average Basic Shares Outstanding | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M |
| Average Diluted Shares Outstanding | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |